文献速递头颈与中枢神经肿瘤

IDH野生型胶质母细胞瘤标准治疗后的分子演化影响生存与精准医学试验设计:EORTC 1542研究

Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study.
PubMed 文献 · J Clin Oncol · 2019-11-19

该研究收集186对接受替莫唑胺放化疗的IDH野生型胶质母细胞瘤原发-复发样本,测序约300个癌症基因。发现分子事件约80%稳定,但所有 examined 基因突变状态均可改变,且强烈影响靶向试验规模与设计;MGMT启动子甲基化状态在复发时仍具预后价值;复发时超突变罕见(8%)且与结局无关。

要点

  • IDH野生型胶质母细胞瘤原发与复发间约80%分子事件稳定,但所有基因突变状态均可改变。
  • 复发时超突变罕见(8%)且与结局无关,对免疫治疗设计有参考意义。
  • MGMT启动子甲基化状态在肿瘤复发时仍保持预后价值。

核心结论

  • IDH野生型胶质母细胞瘤经替莫唑胺放化疗后存在驱动基因不稳定,可影响精准医学试验设计与规模。

研究设计与样本

  • 研究纳入186对原发-复发胶质母细胞瘤样本,患者接受替莫唑胺放化疗,测序约300个癌症基因,并单独检测MGMT、TERT和EGFRvIII状态。

主要发现

  • 队列分子谱与其他胶质母细胞瘤队列一致:IDH野生型占95%,EGFR扩增约50%。
  • IDH野生型胶质母细胞瘤中约80%的分子事件稳定,但所有 examined 基因均观察到突变状态改变,TERT和EGFR突变改变比例分别约为90%和60%。
  • MGMT启动子甲基化肿瘤中观察到类似的驱动基因不稳定模式。
  • MGMT启动子甲基化状态在肿瘤复发时仍具预后价值。
  • 复发时超突变罕见(8%)且与结局无关。

临床怎么用

  • 可基于原发肿瘤分子数据计算复发时按基因或通路的试验规模。
  • 对突变保留率低的基因,需考虑再次手术获取复发样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Precision medicine trials in glioblastoma (GBM) are often conducted at tumor recurrence. However, second surgeries for recurrent GBM are not routinely performed, and therefore, molecular data for trial inclusion are predominantly derived from the primary sample. This study aims to establish whether molecular targets change during tumor progression and, if so, whether this affects precision medicine trial design. MATERIALS AND METHODS: We collected 186 pairs of primary-recurrent GBM samples from patients receiving chemoradiotherapy with temozolomide and sequenced approximately 300 cancer genes. MGMT, TERT, and EGFRvIII status was individually determined. RESULTS: The molecular profile of our cohort was identical to that of other GBM cohorts (IDH wild-type [WT], 95%; EGFR amplified, approximately 50%), indicating that patients amenable to second surgery do not represent a specific molecular subtype. Molecular events in IDH WT GBMs were stable in approximately 80% of events, but changes in mutation status were observed for all examined genes (range, approximately 90% and 60% for TERT and EGFR mutations, respectively), and such changes strongly affected targeted trial size and design. A similar pattern of GBM driver instability was observed within MGMT promoter-methylated tumors. MGMT promoter methylation status remained prognostic at tumor recurrence. The observation that hypermutation at GBM recurrence was rare (8%) and not correlated with outcome was relevant for immunotherapy-based treatments. CONCLUSION: This large cohort of matched primary and recurrent IDH WT tumors establishes the frequency of GBM driver instability after chemoradiotherapy with temozolomide. This allows per gene or pathway calculation of trial size at tumor recurrence, using molecular data of the primary tumor only. We also identify genes for which repeat surgery is necessary because of low mutation retention rate.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Draaisma K, Chatzipli A, Taphoorn M, et al. Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. J Clin Oncol. 2019. PMID: 31743054. doi:10.1200/JCO.19.00367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。